Gastroesophageal reflux disease - Should we adopt a new conceptual framework?

American Journal of Gastroenterology

Volumn 97, Issue 8, 2002, Pages 1901-1909

  Fass, Ronnie ^a,b,d   Ofman, Joshua J ^c  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTON PUMP INHIBITOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 ANTAGONIST; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

BARRETT ESOPHAGUS; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; EROSIVE GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HUMAN; PATHOPHYSIOLOGY; PATIENT CODING; PREVALENCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STOMACH ULCER; TREATMENT OUTCOME;

BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 0036677469     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04269-7     Document Type: Review

References (82)

1. Methodological aspects of evaluation of quality of life in upper gastrointestinal disease
2. Changing trends in esophageal cancer: A 15-year experience in a single center
3. Commentary. The columnar lined oesophagus: A riddle wrapped in a mystery inside an enigma
4. Peptic strictures of the esophagus
5. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response
6. Gastroesophageal reflux disease in primary care in Europe: Clinical presentation and endoscopic findings
7. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease
8. An evidence based appraisal of reflux disease management - The Genval Workshop Report
9. Associations between different forms of gastro-oesophageal reflux disease
10. Diagnosis and assessment of gastrooesophageal reflux disease
11. The endoscopic assessment of oesophagitis: A progress report on observer agreement
12. Review article: Drug therapy for reflux oesophagitis
13. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification
14. Esophageal peristaltic dysfunction in peptic esophagitis
15. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis. The U.S. Multicenter Study
16. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial
17. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis
18. Esomeprazole 20 mg maintains symptom control in endoscopy-negative GERD: A randomized placebo-controlled trial of on-demand therapy for 6 months
19. Focused clinical review - Nonerosive reflux disease
20. Drug therapy for reflux oesophagitis
21. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
22. Gastroesophageal reflux disease and Barrett's esophagus
23. Erosive esophagitis impairs accurate detection of Barrett's esophagus: A prospective randomized double blind study
24. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastro-oesophageal reflux
25. Effect of esophageal emptying and saliva on clearance of acid from the esophagus
26. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis
27. Sustained esophageal contraction: A motor correlate of heartburn symptom
28. Acid gastroesophageal reflux and symptom occurrence: Analysis of some factors influencing their association
29. Non-erosive reflux disease (NERD) - Is it really just a mild form of gastroesophageal reflux disease (GERD)?
30. Reflux symptoms relief with omeprazole in patients without unequivocal oesophagitis
31. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis
32. The effects of ranitidine on symptom relief and quality of life of patients with gastro-esophageal reflux disease
33. Nonerosive reflux disease - Current concepts and dilemmas
34. Extraesophageal presentations of gastroesophageal reflux disease
35. Prevalence of esophagitis in asthmatics
36. Is hoarseness an atypical manifestation of gastroesophageal reflux (GER)? An ambulatory 24-hour pH study
37. Omeprazole for the treatment of posterior laryngitis
38. Lansoprazole treatment of patients with chronic idiopathic laryngitis: A placebo-controlled trial
39. Posterior pharygolaryngitis. Double-blind randomised placebo controlled trial of proton pump inhibitor therapy
40. Natural course of gastroesophageal reflux disease: 17-22 Year follow-up of 60 patients
41. Natural history of gastro-oesophageal reflux disease without oesophagitis
42. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux
43. Esophageal tests in the evaluation of non-cardiac chest pain
44. Healing and relapse of severe peptic esophagitis after treatment with omeprazole
45. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. Follow-up of a randomized controlled trial
46. Barrett syndrome. Case report with discussion about concepts of pathogenesis
47. The columnar-lined esophagus (Barrett syndrome) - An acquired condition?
48. A case of Barrett epithelization followed up for five years
49. The "Barrett syndrome" (the columnar-lined lower esophagus): An acquired condition secondary to reflux esophagitis
50. Critical issues in the management of gastroesophageal reflux disease
51. Barrett's esophagus: Age, prevalence and extent of columnar epithelium
52. Omeprazole as a diagnostic tool in gastroesophageal reflux disease
53. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease
54. The functional esophageal disorders
55. Differential effect of longterm esophageal acid exposure on mechanosensitivity and chemosensitivity in humans
56. Esophageal peristaltic dysfunction in peptic esophagitis
57. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: A randomized, double-blind, placebo-controlled study of efficacy and safety
58. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis?
59. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis
60. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis
61. The symptom index: A clinically important parameter of ambulatory 24-hour esophageal pH monitoring
62. Correlation of oesophageal acid exposure with Barrett's oesophagus length
63. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma
64. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients
65. Barrett's esophagus: Age, prevalence, and extent of columnar epithelium
66. The Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on diagnosis, surveillance, and therapy of Barrett's esophagus
67. Regression of Barrett's esophagus: The role of acid suppression, surgery, and ablative methods
68. Partial regression of Barrett's esophagus by long-term therapy with high dose omeprazole
69. Is long-term esophageal pH monitoring of clinical value?
70. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease
71. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux: The "sensitive oesophagus"
72. Chest pain of esophageal origin
73. Contribution of central sensitisation to the development of non-cardiac chest pain
74. Visceral hyperalgesia revisited
75. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor
76. Long-term omeprazole treatment in resistant gastroesophageal reflux disease. Efficacy, safety, and influence on gastric mucosa
77. Maximal acid reflux control for Barrett's oesophagus: Feasible and effective
78. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose inhibition: A multicenter study